Annual report
4564.TEDINET S100OBQJ
Period2021-04-01 → 2022-03-31
Filed2022-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥332m | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Operating income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.0bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥3.0bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.9bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | −¥1.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.4bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥5.1bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.0bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥291m | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.7bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.7bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥3.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥31m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥74m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥446m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥566m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥151m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.86 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.73 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.9 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.39 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥16.96 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥25.81 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥30.32 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥47.44 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.8% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.0% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 67 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 66 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 62 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 63 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 56 | at 2018-03-31d | Cons. | Number of employees |
| Operating income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | −¥1.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.5bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | −¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥3.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.6bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.1bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.9bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥4.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.5bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥418m | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥245m | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.1bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.13 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.05 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.85 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥14.53 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥23.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥25.75 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.89 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 151,557,400 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 147,032,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 36 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 35 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 32 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 37 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 40 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥952,000 |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥683m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥368m |
| Cancer Precision Medical Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥468m |
| Cancer Precision Medical Businessreportable segment | employees | at 2022-03-31 | 31 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2022-03-31 | ¥1.0bn |
| Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥49m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2022-03-31 | 36 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥166,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2022-03-31 | ¥2.3bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥1.6bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥469m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥11m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9m |
| —segment total | segment assets | at 2022-03-31 | ¥3.4bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥29m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥15m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥50m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥50m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥6m |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥214m |
| Cancer Precision Medical Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥11m |
| Cancer Precision Medical Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥272m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥221m |
| Cancer Precision Medical Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥50m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2021-03-31 | ¥254m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥293m |
| Research And Development Of Pharmaceutical Productsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥34m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥111m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥111m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥55,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2021-03-31 | ¥3.1bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥1.1bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥13m |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥34m |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥383m |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥332m |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥50m |
| —segment total | segment assets | at 2021-03-31 | ¥3.4bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | −¥1.4bn |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2022-03-31 | 36 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,183
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -1814854000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -1062186000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4713947000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2899092000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2899092000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 1836906000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 2 | |
| Outsourcing expenses research and development expenses | Prior1YearDuration | 594843000 | JPY |
| Outsourcing expenses research and development expenses | CurrentYearDuration | 1079339000 | JPY |
| Payrolls and allowances research and development expenses | Prior1YearDuration | 185345000 | JPY |
| Payrolls and allowances research and development expenses | CurrentYearDuration | 172335000 | JPY |
| Commission fee sga | Prior1YearDuration | 89389000 | JPY |
| Commission fee sga | CurrentYearDuration | 81239000 | JPY |
| Directors compensations sga | Prior1YearDuration | 58725000 | JPY |
| Directors compensations sga | CurrentYearDuration | 54125000 | JPY |
| Payroll and allowances sga | Prior1YearDuration | 68168000 | JPY |
| Payroll and allowances sga | CurrentYearDuration | 70971000 | JPY |
| Taxes and dues sga | Prior1YearDuration | 1587000 | JPY |
| Taxes and dues sga | CurrentYearDuration | 142011000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 110993000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 221484000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 332477000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 332477000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 55000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 50064000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 50120000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -50120000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 111049000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 271548000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 382598000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -50120000 | JPY |
| Net sales | Prior1YearDuration | 332477000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -1130736000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -293129000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | -1423865000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -214070000 | JPY |
| Operating income | Prior1YearDuration | -1637936000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 3107906000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 254119000 | JPY |
| Assets | Prior1YearInstant_ReportableSegmentsMember | 3362025000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 6076000 | JPY |
| Assets | Prior1YearInstant | 3368102000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 34305000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Depreciation segment information | Prior1YearDuration_ReportableSegmentsMember | 34305000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | 14703000 | JPY |
| Depreciation segment information | Prior1YearDuration | 49008000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 1899000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |